These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 2872529)

  • 1. Very-low-dose cytarabine for elderly patients.
    Pesce A; Cassuto JP; Bayle J; Raynaud S; Fuzibet JG; Gratecos N; Dujardin P
    Lancet; 1986 Jun; 1(8495):1436. PubMed ID: 2872529
    [No Abstract]   [Full Text] [Related]  

  • 2. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukemias and myelodysplastic syndromes.
    Tambone Reyes M; Bonaccorso R; Gebbia V; Tinnirello D; Di Salvo V; Ciulla A; Di Marco P; Mansueto S; Citarrella P
    J Chemother; 1989 Jul; 1(4 Suppl):1276-8. PubMed ID: 16312864
    [No Abstract]   [Full Text] [Related]  

  • 3. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic data on very-low-dose cytarabine.
    Poirier O; Chomienne C; Castaigne S; Degos L; Abita JP; Najean Y
    Lancet; 1986 Jun; 1(8495):1436-7. PubMed ID: 2872530
    [No Abstract]   [Full Text] [Related]  

  • 5. FLAGIDA-lite is an effective regimen for patients between 70 and 80 years with acute myeloid leukemia or refractory anemia with excess blasts-2 and is feasible as outpatient treatment.
    Bermúdez A; Pérez-Vázquez G; Insunza A; Baro J; Colorado M; Conde E; Díez-Gallarreta Z; Gutiérrez ML; López-Duarte M; Olalla I; Sanroma P; Yañez L; Iriondo A; Richard C
    Am J Hematol; 2012 Jan; 87(1):42-4. PubMed ID: 22015963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral idarubicin in elderly acute leukemia and refractory anemia with excess of blasts.
    Berrebi A; Polliack A
    Haematol Blood Transfus; 1990; 33():342-5. PubMed ID: 2323640
    [No Abstract]   [Full Text] [Related]  

  • 7. An inexpensive way to treat elderly patients with high-risk MDS or AML.
    Kuendgen A
    Leuk Res; 2011 Aug; 35(8):985-6. PubMed ID: 21561661
    [No Abstract]   [Full Text] [Related]  

  • 8. Results of aggressive chemotherapy for myelodysplastic syndromes.
    Dohy H; Kyo T
    Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1428-34. PubMed ID: 3247817
    [No Abstract]   [Full Text] [Related]  

  • 9. Small-dose cytosine arabinoside in the treatment of elderly patients with acute leukemia and refractory anemia with excess of blast.
    Satou Y; Kubota T; Yonekura S; Noguchi K; Oobayashi Y; Nagao T; Arimori S
    Tokai J Exp Clin Med; 1986 Oct; 11(4):249-54. PubMed ID: 3617109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
    Tsimberidou A; Estey E; Cortes J; Thomas D; Faderl S; Verstovsek S; Garcia-Manero G; Keating M; Albitar M; O'Brien S; Kantarjian H; Giles F
    Cancer; 2003 Mar; 97(6):1481-7. PubMed ID: 12627513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
    Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
    Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Exudative pericardial effusion and oligoarthritis in a patient newly diagnosed with myelodysplastic syndrome].
    Fernández-Sojo J; Vives S; Oliveras Vilà T; Ribera JM
    Med Clin (Barc); 2014 Jul; 143(1):43-4. PubMed ID: 24183124
    [No Abstract]   [Full Text] [Related]  

  • 13. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
    Estey EH; Kantarjian H; Keating M
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose cytosine arabinoside in refractory anemia with excess of blasts in transformation.
    Fridrik MA; Wahl G; Herbinger W
    Blut; 1988 Dec; 57(6):357-60. PubMed ID: 3207893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM.
    Natarajan-Amé S; Park S; Ades L; Vey N; Guerci-Bresler A; Cahn JY; Etienne G; Bordessoule D; Ravoet C; Legros L; Cheze S; Stamatoullas A; Berger E; Schmidt A; Charbonnier A; Chaury MP; Braun T; Fenaux P; Dreyfus F;
    Br J Haematol; 2012 Jul; 158(2):232-237. PubMed ID: 22571447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
    Corsetti MT; Salvi F; Perticone S; Baraldi A; De Paoli L; Gatto S; Pietrasanta D; Pini M; Primon V; Zallio F; Tonso A; Alvaro MG; Ciravegna G; Levis A
    Leuk Res; 2011 Aug; 35(8):991-7. PubMed ID: 21474179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Low dose Ara-C for remission induction in aged patients with atypical nonlymphocytic leukemia and refractory anemia with excess blasts].
    Sawada H; Yamagishi M; Mochizuki T; Ishikura H; Izumi Y; Park YH; Wano M; Usui T; Uchino H
    Rinsho Ketsueki; 1983 Nov; 24(11):1464-72. PubMed ID: 6584648
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
    Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
    Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Low doses of subcutaneous cytosine arabinoside in the treatment of patients with myelodysplastic syndromes].
    Avilés A; Tripp F; Velásquez A; Rubio ME; González-Llavén J
    Rev Invest Clin; 1988; 40(1):21-4. PubMed ID: 3165541
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy of low-dose cytarabine after failure of conventional chemotherapy].
    Leverger G; Valensi F; Daniel MT; Schaison G; Bancillon A; Castaigne S
    Presse Med; 1985 Sep; 14(29):1562. PubMed ID: 2932699
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.